$FTLF
FITLIFE BRANDS, INC. Stock $ftlf

$ftlf Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000143774924026562 Filed on August 14, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$15.98M	$16.93M
YoY Change	14.93%	14.7%
Cost Of Revenue	$8.976M	$9.350M
YoY Change	9.38%	6.31%
Gross Profit	$7.001M	$7.580M
YoY Change	22.91%	27.07%
Gross Profit Margin	43.82%	44.77%
Selling, General & Admin	$2.645M	$2.528M
YoY Change	-16.61%	-22.05%
% of Gross Profit	37.78%	33.35%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$15.00K	$16.00K
YoY Change	36.36%	23.08%
% of Gross Profit	0.21%	0.21%
Operating Expenses	$3.819M	$3.905M
YoY Change	18.38%	15.5%
Operating Profit	$3.182M	$3.675M
YoY Change	28.83%	42.22%
Interest Expense	-$286.0K	-$318.0K
YoY Change	-214.86%	-226.69%
% of Operating Profit	-8.99%	-8.65%
Other Income/Expense, Net	-$286.0K	-$318.0K
YoY Change	-15.88%	-2220.0%
Pretax Income	$2.896M	$3.357M
YoY Change	35.96%	29.17%
Income Tax	$770.0K	$729.0K
% Of Pretax Income	26.59%	21.72%
Net Earnings	$2.126M	$2.628M
YoY Change	25.35%	33.81%
Net Earnings / Revenue	13.31%	15.52%
Basic Earnings Per Share	$0.46	$0.57
Diluted Earnings Per Share	$0.43	$0.53
COMMON SHARES
Basic Shares Outstanding	4.598M	4.598M
Diluted Shares Outstanding	4.965M	4.950M

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.664M	$3.680M
YoY Change	-36.48%	-58.57%
Cash & Equivalents	$4.720M	$3.735M
Short-Term Investments
Other Short-Term Assets	$998.0K	$966.0K
YoY Change	-43.17%	-36.45%
Inventory	$10.37M	$9.779M
Prepaid Expenses
Receivables	$2.008M	$2.498M
Other Receivables	$58.00K	$111.0K
Total Short-Term Assets	$18.10M	$17.03M
YoY Change	-7.31%	-24.11%
LONG-TERM ASSETS
Property, Plant & Equipment	$91.00K	$106.0K
YoY Change	-54.27%	-34.57%
Goodwill	$13.13M	$13.11M
YoY Change	-1.43%	-3.33%
Intangibles	$26.31M	$26.31M
YoY Change	239.71%	230.63%
Long-Term Investments
YoY Change
Other Assets	$522.0K	$682.0K
YoY Change	-82.82%	-49.26%
Total Long-Term Assets	$40.49M	$40.28M
YoY Change	65.63%	73.71%
TOTAL ASSETS
Total Short-Term Assets	$18.10M	$17.03M
Total Long-Term Assets	$40.49M	$40.28M
Total Assets	$58.59M	$57.31M
YoY Change	33.24%	25.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.078M	$4.309M
YoY Change	71.42%	20.67%
Accrued Expenses	$1.046M	$1.140M
YoY Change	-45.58%	-63.89%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.500M	$4.500M
YoY Change	80.0%	80.0%
Total Short-Term Liabilities	$12.06M	$12.32M
YoY Change	63.17%	25.53%
LONG-TERM LIABILITIES
Long-Term Debt	$9.664M	$10.78M
YoY Change	10.45%	14.97%
Other Long-Term Liabilities	$352.0K	$25.00K
YoY Change	496.61%	-70.59%
Total Long-Term Liabilities	$9.664M	$10.78M
YoY Change	10.45%	14.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.06M	$12.32M
Total Long-Term Liabilities	$9.664M	$10.78M
Total Liabilities	$24.43M	$25.46M
YoY Change	30.48%	16.85%
SHAREHOLDERS EQUITY
Retained Earnings	$3.497M	$1.371M
YoY Change	-171.41%	-120.79%
Common Stock	$46.00K	$46.00K
YoY Change	4.55%	4.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$34.16M	$31.86M
YoY Change
Total Liabilities & Shareholders Equity	$58.59M	$57.31M
YoY Change	33.24%	25.59%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	$2.126M	$2.628M
YoY Change	25.35%	33.81%
Depreciation, Depletion And Amortization	$15.00K	$16.00K
YoY Change	36.36%	23.08%
Cash From Operating Activities	$2.047M	$1.570M
YoY Change	109.3%	0.51%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change	-100.0%
Cash From Investing Activities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.125M	-1.125M
YoY Change	80.0%	80.0%
NET CHANGE
Cash From Operating Activities	2.047M	1.570M
Cash From Investing Activities	0.000	0.000
Cash From Financing Activities	-1.125M	-1.125M
Net Change In Cash	922.0K	445.0K
YoY Change	-162.38%	-49.6%
FREE CASH FLOW
Cash From Operating Activities	$2.047M	$1.570M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	$2.047M	$1.570M
YoY Change	110.6%	4.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Gross Profit GrossProfit	7580000	usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001374328
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q2	us-gaap	Cash Cash	3680000	usd
CY2023Q4	us-gaap	Cash Cash	1139000	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	55000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	759000	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	18000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	17000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2498000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2046000	usd
CY2024Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	69000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	162000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	9779000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	9091000	usd
CY2024Q2	ftlf	Sales Taxes Receivable SalesTaxesReceivable	111000	usd
CY2023Q4	ftlf	Sales Taxes Receivable SalesTaxesReceivable	1019000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	911000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	639000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	17034000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	14693000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	106000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	137000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	73000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	121000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	134000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	113000	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26308000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26309000	usd
CY2024Q2	us-gaap	Goodwill Goodwill	13108000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	13294000	usd
CY2024Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	682000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	792000	usd
CY2024Q2	us-gaap	Assets Assets	57311000	usd
CY2023Q4	us-gaap	Assets Assets	55346000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4309000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3261000	usd
CY2024Q2	ftlf	Accrued Expense And Other Liabilities Current AccruedExpenseAndOtherLiabilitiesCurrent	1082000	usd
CY2023Q4	ftlf	Accrued Expense And Other Liabilities Current AccruedExpenseAndOtherLiabilitiesCurrent	1026000	usd
CY2024Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1844000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	892000	usd
CY2024Q2	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	530000	usd
CY2023Q4	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	571000	usd
CY2024Q2	us-gaap	Loans Payable Current LoansPayableCurrent	4500000	usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	4500000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	58000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	87000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	12323000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10337000	usd
CY2024Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	10778000	usd
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	15509000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	25000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	51000	usd
CY2024Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2329000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2413000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	25455000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	28310000	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4598000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4598000
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4598000
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4598000
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	46000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	30902000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1371000	usd
CY2024Q2	us-gaap	Translation Adjustment Functional To Reporting Currency Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax	-463000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	31856000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57311000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	16930000	usd
CY2024Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9350000	usd
CY2024Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	1326000	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2528000	usd
CY2024Q2	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	24000	usd
CY2024Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	27000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	3905000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	3675000	usd
CY2024Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	17000	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	345000	usd
CY2024Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	10000	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-318000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3357000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	729000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	2628000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.57
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.53
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4598000
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4950000
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	2628000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-250000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2378000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	29377000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	101000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-250000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	2628000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	31856000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	27036000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	203000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-171000	usd
	us-gaap	Net Income Loss NetIncomeLoss	4788000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	31856000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	21608000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	31000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	247000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	1964000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	23850000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	21388000	usd
	ftlf	Shares Surrendered By Former Employee SharesSurrenderedByFormerEmployee	-1000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	74000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	269000	usd
	us-gaap	Net Income Loss NetIncomeLoss	2120000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	23850000	usd
	us-gaap	Net Income Loss NetIncomeLoss	4788000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	63000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	-93000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	203000	usd
	ftlf	Amortization Of Deferred Finance Costs AmortizationOfDeferredFinanceCosts	19000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	480000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	641000	usd
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-110000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-770000	usd
	ftlf	Operating Lease Rightofuse Asset Net Of Amortization And Lease Liability OperatingLeaseRightofuseAssetNetOfAmortizationAndLeaseLiability	-45000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1064000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-53000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	851000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-41000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6606000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10000	usd
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	-0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17153000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	4750000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	625000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4750000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11875000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-9000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	40000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1837000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3444000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1898000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13277000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3735000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	517000	usd
	us-gaap	Interest Paid Net InterestPaidNet	761000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE 1 - DESCRIPTION OF BUSINESS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Summary</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">FitLife Brands, Inc. (the “<i>Company</i>”) is a provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, “<i>NDS Products</i>”); (ii) iSatori, BioGenetic Laboratories, and Energize (together, the "<i>iSatori Products</i>"); (iii) Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the “<i>MRC Products</i>"); and (iv) MusclePharm.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company distributes the NDS Products principally through franchised General Nutrition Centers, Inc. (“<i>GNC</i>”) stores located both domestically and internationally and, with the launch of Metis Nutrition, through corporate GNC stores in the U.S. The iSatori Products are sold through approximately 16,000 retail locations, which include specialty and mass, as well as online directly to the end consumer. The Company distributes the MRC Products primarily online through e-commerce platforms, such as Amazon, directly to the end consumer. MusclePharm’s products are sold to both wholesale customers as well as online through various e-commerce platforms directly to the end consumer.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">FitLife Brands is headquartered in Omaha, Nebraska. For more information on the Company, please go to www.fitlifebrands.com. The Company’s common stock, par value $0.01 per share (“<i>Common Stock</i>”), trades under the symbol “FTLF” on the Nasdaq Capital Market.</p>
	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE 2 - BASIS OF PRESENTATION</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation are included. Operating results for the three- and six-month periods ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. Although management of the Company believes the disclosures presented herein are adequate and not misleading, these interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the footnotes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (the “<i>SEC</i>”) on March 29, 2024.</p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Use of Estimates and Assumptions</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales and expense recognized during the periods presented.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Those estimates and assumptions include estimates for reserves of uncollectible accounts receivable, allowance for inventory obsolescence, product returns, depreciable lives of property and equipment, allocation of purchase price from business combinations, analysis of impairment of goodwill, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Customer and Vendor Concentration</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Net sales to GNC during the three-month periods ended June 30, 2024 and 2023 represent 23% and 29% of total net revenue, respectively. Net sales to GNC during the six-month periods ended June 30, 2024 and 2023 represent 24% and 37% of total net revenue, respectively. Gross accounts receivable attributable to GNC represented 16% and 30% of the Company’s total accounts receivable balance as of June 30, 2024 and December 31, 2023, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of June 30, 2024 and December 31, 2023, there was <span style="-sec-ix-hidden:c437"><span style="-sec-ix-hidden:c438">one</span></span> vendor who accounted for more than 10% of the Company's consolidated accounts payable. During the six months ended June 30, 2024 and 2023, there were <span style="-sec-ix-hidden:c441"><span style="-sec-ix-hidden:c442">two</span></span> vendors who each accounted for over 10% of the Company’s inventory-related purchases.</p>
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.24	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.33	pure
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	2628000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	1964000	usd
	us-gaap	Net Income Loss NetIncomeLoss	4788000	usd
	us-gaap	Net Income Loss NetIncomeLoss	2120000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4598000
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4446000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4598000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4464000
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	352000
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	441000
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	333000
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	442000
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4950000
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4887000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4931000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4906000
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.57
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.44
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.47
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.53
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.4
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.97
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.43
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Reclassifications</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Certain reclassifications have been made in the Company’s financial statements. Advertising and marketing expense for the three and six months ended June 30, 2023 were previously reported as part of selling, general and administrative expense. Advertising and marketing expense is now segregated and reported separately in the accompanying statement of income and comprehensive income to conform to current period presentation. These reclassifications had no impact on earnings or stockholders’ equity.</p>
CY2024Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	69000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	162000	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	8863000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	8292000	usd
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	985000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	961000	usd
CY2024Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	69000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	162000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	9779000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	9091000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	965000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	954000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	859000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	817000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	106000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	137000	usd
CY2024Q2	us-gaap	Depreciation Depreciation	16000	usd
CY2023Q2	us-gaap	Depreciation Depreciation	13000	usd
	us-gaap	Depreciation Depreciation	42000	usd
	us-gaap	Depreciation Depreciation	22000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	10778000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	15509000	usd
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4598000
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	160000
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	468000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	484000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.82
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y6M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	-0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	-0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	484000
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.82
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y
CY2024Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	484000
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P4Y
CY2024Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	6.82
CY2024Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	401000
CY2024Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	4.31
CY2024Q1	us-gaap	Share Price SharePrice	33.3
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	12825000	usd
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	537000	usd

Files In Submission

Name	View Source	Status
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
0001437749-24-026562-index-headers.html	Edgar Link	pending
0001437749-24-026562-index.html	Edgar Link	pending
0001437749-24-026562.txt	Edgar Link	pending
0001437749-24-026562-xbrl.zip	Edgar Link	pending
ex_711571.htm	Edgar Link	pending
ex_711572.htm	Edgar Link	pending
ex_711573.htm	Edgar Link	pending
ex_711574.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ftlf-20240630.xsd	Edgar Link	pending
ftlf20240630_10q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
ftlf-20240630_cal.xml	Edgar Link	unprocessable
ftlf-20240630_def.xml	Edgar Link	unprocessable
ftlf-20240630_lab.xml	Edgar Link	unprocessable
ftlf-20240630_pre.xml	Edgar Link	unprocessable
ftlf20240630_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FTLF
FITLIFE BRANDS, INC. Stock $ftlf

2024 Q3 Form 10-Q Financial Statement

#000143774924026562 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FTLF FITLIFE BRANDS, INC. Stock $ftlf

2024 Q3 Form 10-Q Financial Statement

#000143774924026562 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FTLF
FITLIFE BRANDS, INC. Stock $ftlf